Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
Publication Type:
Journal Article
Authors:
Afdhal, N.H.;
Reddy, K.R.;
David R. Nelson;
E J Lawitz;
Gordon, S.C.;
E R Schiff;
Nahass, R.;
Ghalib, R.;
Gitlin, N.;
Herring, R.;
Lalezari, J.;
Younes, Z.H.;
Pockros, P.J.;
A M Di Bisceglie;
Arora, S.;
Subramanian, G.M.;
Zhu, Y.;
Dvory-Sobol, H.;
Yang, J.C.;
Pang, P.S.;
Symonds, W.T.;
McHutchison, J.G.;
Muir, A.J.;
M S Sulkowski;
Kwo, P.Y.;
ION-2 investigatorsSource:
N Engl J Med, Volume 370, Issue 16, p.1483-1493 (2014)
Keywords:
administration & dosage,
Adult,
adverse effects,
Aged,
analogs & derivatives,
antagonists & inhibitors,
Antiviral Agents,
Baltimore,
Benzimidazoles,
Boston,
California,
Cities,
clinical trial,
Disease,
Drug Combinations,
drug therapy,
Fatigue,
Female,
Florida,
Fluorenes,
genetics,
Genotype,
genotype 1,
HCV,
Headache,
Health,
Hepacivirus,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
Humans,
Infection,
Israel,
Liver,
Liver Diseases,
Male,
Medicine,
methods,
Mexico,
Middle Aged,
Multicenter Studies,
Nausea,
New Mexico,
NS5A inhibitor,
Nucleotidyltransferases,
Patients,
peginterferon,
Philadelphia,
protease inhibitor,
Proteins,
Research,
Research Support,
Ribavirin,
Rna,
RNA Replicase,
San Francisco,
sofosbuvir,
sustained virologic response,
Tennessee,
Texas,
therapeutic use,
therapy,
treatment,
Uridine,
Uridine Monophosphate,
Viral Load,
Viral Nonstructural Proteins,
virology
